Glucagon (19-29), human是高效的胰岛素分泌抑制剂。

体外研究：

Glucagon (19-29), from 0.1 pM to 1 nM, exerts a potent negative inotropic action. The most striking observation is a 45% increase in the amplitude of cell contractility elicited by the combination of 30 nM glucagon with 1 nM Glucagon (19-29)[3]

体内研究：

Glucagon (19-29), also named Miniglucagon, is the COOH-terminal (19-29) fragment processed from glucagon. Glucagon (19-29) dose-dependently inhibits insulin secretion stimulated by 8.3 M glucose, with no change in the perfusion flow rate. A concentration of 1 nM Glucagon (19-29) has a significant inhibitory effect on a 1 nM glucagon-like peptide 1 (7-36) amide–potentiated insulin secretion[1]. Glucagon (19-29) is a highly potent and efficient inhibitor of insulin release by closing, via hyperpolarization, voltage-dependent Ca2+ channels linked to a pathway involving a pertussis toxin-sensitive G protein[2].

单字母 H2N-AQDFVQWLMNT-OH
多字母 H2N-Ala-Gln-Asp-Phe-Val-Gln-Trp-Leu-Met-Asn-Thr-OH
氨基酸个数 11
分子式 C61H89N15O18S1
平均分子量(MW) 1352.51
精确分子量(Exact Mass)(MW) 1351.62
等电点(PI) 6.26
pH=7.0时的净电荷数 -0.02
GRAVY -0.1
亲水残基比例 0.08
消光系数 5500
溶解建议 疏水

参考文献:
Miniglucagon (glucagon 19-29): a novel regulator of the pancreatic islet physiology【DOI: 10.2337/diabetes.51.2.406】